1,026 Healthcare Names, 9 Clear the Data

The Setup

Last Friday, in The Chip Selloff, Measured, we ran 39 semiconductor names through the platform to find out how much of the dip was actually value. The answer was: less than the bounce suggested. This week the monthly Sector Spotlight rotation moves to healthcare, and the exercise is the same with the dial turned up. Every tracked healthcare name carrying a Company Strength score, a Fair Value score, and an Outlook rating went through the screen. That is 1,026 companies, from $160 billion pharmaceutical franchises down to single-product biotechs with one drug and a burn rate.

The first result is the one worth sitting with. Of those 1,026 names, 713 score Weak and another 130 score Avoid on Company Strength. That is 82% of the sector failing the quality screen outright. Only 31 rate Strong. Only three rate Elite. On the outlook side, the engine is Bullish on 81 names, 7.9% of the sector, against 400 Bearish and 52 Avoid. Healthcare is not a market having a quiet year. It is a market where a very small number of businesses are working and a very large number are not, and the index return hides both facts at once.

Applying all three gates together, Elite or Strong on quality, Bullish on outlook, and trading below fair value on the valuation model, leaves nine names out of 1,026. Two more qualified on the labels and were removed on data integrity: Innoviva printed a calculated upside of 249.8% and Novo Nordisk printed 409.4%, both far outside the 80 to 100 percent reliability band where this platform stops trusting its own fair value output. Those are not opportunities, they are model artifacts, and naming them is cheaper than pretending the screen produced eleven. What follows is five of the nine, ordered by Company Strength, followed by an honest accounting of the four left on the table.

Two Markets, One Sector Label

Start with the price action, because it sets up the inversion. Year to date, the broad healthcare ETF is up 5.5% while the S&P 500 is up 11.7%. A six-point lag. Unremarkable. Now split it: the biotech ETF is up 25.2%, the broader biotech index is up 13.0%, and the medical device index is down 13.6%. The gap between the best and worst corners of a single sector is roughly 39 percentage points. Anyone holding healthcare as one allocation has been holding two unrelated bets.

Here is where the scores do something the charts do not. Biotech is by far the largest sub-sector in the scan at 569 of the 1,026 names, and it carries the lowest Bullish rate in the sector at 3.3%. Medical devices and instruments, the corner that just lost 13.6%, run 12.3%. Providers and care facilities lead everything at 23.2%. Pharma sits at 11.4%, health information services at 17.4%.

Read that again in plain terms: the sub-sector that has run the hardest this year contains the smallest share of names the engine has conviction in, and the sub-sector that has been taken apart contains nearly four times that share. That is not a contradiction, it is what a rally in an asset class full of pre-revenue companies looks like from the inside. The biotech tape is being set by names with no earnings to score. XBI going up 25% and the platform finding almost nothing to like inside biotech are the same fact viewed from two angles.

It also means the five below are not a bet on the healthcare trade. Three of them sit in the sub-sector with the worst Bullish rate in the entire scan. They are there because they carry earnings, filings, and balance sheets that clear a quality bar 82% of their sector does not, which is a different thing entirely from being in the right corner of the tape.

Exelixis (EXEL)

Company Strength 83.8, Elite. Fair Value $61.37, Undervalued by 17.6%. Outlook: Bullish.

Exelixis is one of only three Elite-rated companies in a 1,026-name sector, and the only one of the three that is also trading below fair value. The scores behind that rating are uniformly strong rather than lopsided: Financial Health 82/100, Moat 13/15, Growth 13/15. In a sub-sector where the median name is a cash-burning single-asset story, this is an oncology business that funds itself.

The second quarter, reported August 5, showed why. Total revenue of $628.7 million, up 10.6% year over year. GAAP net income of $212 million, with diluted EPS rising to $0.82 from $0.65. The global cabozantinib franchise, including partner sales, reached $806 million, up roughly 13%. Cash and marketable securities stood at approximately $1.4 billion, and the company repurchased about $312 million of stock in the quarter alone, retiring roughly 6.5 million shares at an average price near $47.

The honest counterweight is that the same report contained a guidance cut. Management lowered full-year revenue expectations by roughly $50 million at the midpoint, citing slower patient uptake in the neuroendocrine tumor indication, and the stock fell about 5% on the news. The forward case now leans harder on zanzalintinib, where the FDA has a target action date of December 3, 2026 for the colorectal cancer application and six further pivotal trials are running. That is a real binary sitting four months out, and the fair value model has no way to price which way it breaks.

Aurinia Pharmaceuticals (AUPH)

Company Strength 79.6, Strong. Fair Value $23.34, Deep Value at 44.7% below. Outlook: Bullish.

Aurinia carries the second-highest strength score in the qualifying group and the widest usable discount of the five. It is also the smallest company here by a wide margin, and the one whose case rests on a single product: LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis. Growth scores 14/15, the highest reading in the entire list, with Financial Health at 74/100 and Moat at 12/15.

The company reported second quarter results on August 6: total revenue of $83.2 million, up 19% year over year, with LUPKYNIS net product sales of $79.4 million, also up 19%. Net income was $37.4 million against $21.5 million a year earlier, and diluted EPS reached $0.28 from $0.16. Cash, equivalents, restricted cash and investments totaled $443.1 million. Full-year guidance was reiterated at $315 million to $325 million. This is a profitable small-cap biotech generating operating cash and buying back its own stock, which describes very few of the 569 biotech names in the scan.

The concentration is the risk and it is not a small one. LUPKYNIS represents roughly 95% of revenue, which means any competitive entry, reimbursement change, or patent challenge lands on the whole company at once. The pipeline answer is aritinercept, now in clinical development across multiple autoimmune indications, but that is early and unpriced. It is also worth noting that at least one widely followed third-party model puts Aurinia's fair value near the current price rather than 45% above it. The platform's number and the street's number disagree here, and the analysis does not get to pretend otherwise.

Regeneron (REGN)

Company Strength 72.2, Strong. Fair Value $924.97, Undervalued by 20.4%. Outlook: Bullish.

Regeneron is the large-cap anchor of this list and the clearest example of the year's central healthcare disconnect: a company posting double-digit growth on both lines while its stock sits roughly flat, down 1.1% year to date. Financial Health scores 78/100 and Moat 12/15. Growth, at 9.5/15, is the softest reading among the five and reflects a franchise transition rather than a franchise failure.

The most recent quarter put revenue at $4.3 billion, up 17%, the second consecutive quarter of double-digit growth on both revenue and non-GAAP earnings per share. Global Dupixent net sales, recorded by partner Sanofi, rose 38% to an all-time high of $6.0 billion. EYLEA HD sales in the United States rose 52%, also to a record. Libtayo grew 30%. The company reports approximately 50 clinical assets in development.

The reason the market has not paid for this is the older EYLEA franchise, where biosimilar and competitive erosion has been eating the base for several quarters. The bull case is that EYLEA HD converts the franchise forward faster than the legacy product declines, and the 52% growth number is the evidence for it. The bear case is that conversion economics are worse than replacement economics and the market has already done that math. The valuation model reads the current filings and calls the stock 20% cheap. It is not pricing how the erosion curve and the conversion curve intersect two years out, because it cannot.

Zoetis (ZTS)

Company Strength 70.2, Strong. Fair Value $91.50, Undervalued by 23.0%. Outlook: Bullish.

This is the name on the list that requires the most transparency, so it gets it up front. Zoetis is the world's largest animal health company and it is down 38.7% year to date and roughly 51% over the past 52 weeks. On May 7 it lost 21.5% in a single session after a first quarter miss and a guidance cut. Then, on the morning of August 6, it cut guidance again.

The second quarter numbers: revenue of $2.468 billion, essentially flat and down 1% organically. GAAP net income fell 5% to $691 million. Adjusted EPS rose 5% to $1.87, helped by a share count that dropped roughly 6.2%. Underneath, the United States segment declined 7%, US companion animal fell 11%, and the core dermatology franchise dropped 16%. Livestock grew 11% and international grew 6%, which cushioned the quarter without saving it. Management revised full-year revenue guidance down to $9.12 billion to $9.32 billion from $9.68 to $9.96 billion, now modeling organic revenue declining 3% to 1%, and lowered adjusted EPS guidance to $6.15 to $6.25 from $6.85 to $7.00. The CFO stated that July sales trends had not yet indicated market stabilization.

So why is it here? Because the screen is mechanical and the mechanics still pass: the Company Strength score of 70.2 reflects a business with Financial Health of 78/100, a Moat of 12/15, roughly 65% of revenue in companion animal and 35% in production animal, and the largest market share in its industry across more than 100 countries. That is what the model measures, and none of it stopped being true this week. What the model has not yet absorbed is the guidance cut itself, and readers should know exactly why: the Company Strength scores in this scan carry a calculation date of August 1. Zoetis reported on August 6. The valuation and outlook readings are current to August 6, the quality reading is five days behind the news, and the honest description of Zoetis today is a structurally dominant franchise in a demand environment its own management says has not stabilized.

Gilead Sciences (GILD)

Company Strength 70.0, Strong. Fair Value $154.09, Undervalued by 17.8%. Outlook: Bullish.

Gilead is the repeat qualifier. It appeared in Strong and Undervalued on June 5, and two months later it still clears all three gates, which is the kind of thing this franchise exists to report. Financial Health scores 80/100 and Growth 12/15. The Moat reading of 9/15 is the weakest of the five and is the model registering what patent-cliff exposure does to a pharmaceutical moat regardless of current franchise strength.

The second quarter showed base business revenue growth of 10% year over year, with the HIV portfolio up 12% on treatment strength and rapid expansion of the PrEP business, plus contributions from Trodelvy and Livdelzi. Management raised base business revenue expectations for 2026 and pointed to three FDA approvals and three positive Phase 3 updates in the quarter, with two further potential launches in oncology and HIV in the second half.

And then there is the headline that will confuse anyone who looks the stock up: Gilead reported a GAAP loss of $8.45 per share for the quarter, and its full-year guidance now contemplates a GAAP loss as well. That is not an operating collapse. It is roughly $11.1 billion of acquired in-process research and development expense from the Arcellx, Tubulis, and Ouro Medicines transactions, which accounting rules require be written off immediately rather than capitalized. The base business grew 10%. The accounting treatment of three acquisitions produced the loss. Both statements are true, and the second one is the reason the valuation model, which works from normalized earnings power rather than the GAAP headline, still reads the stock at a discount.

What the Wealth Engine Scores Say

Here is the platform's systematic read on all five, ordered as they appear above. Company Strength readings carry a calculation date of August 1; Fair Value and Outlook are current to August 6.

Five names, five green rows, which is exactly what a three-gate screen is supposed to produce and exactly why the caveat above it matters more than usual this week. Four of these five reported second quarter results in the eight days before publication, and the Company Strength model last ran on August 1. The quality column is reading filings that in most cases predate the newest quarter. Fair Value and Outlook are current.

These scores are systematic. They evaluate companies based on reported financials, balance sheet quality, moat characteristics, and valuation models (DCF, peer comparison, earnings power). They measure what a company is today, not what it might become. That is by design: the scoring system is built to keep emotion and forward speculation out of the numbers.

This article is doing something different. It is naming where the newest information cuts against the score, most sharply at Zoetis, where management lowered full-year guidance for the second time in three months on the morning of August 6, and at Exelixis, where a revenue guidance cut arrived alongside an earnings beat on August 5. The scoring system will absorb both on its next run. It has not yet.

Both perspectives are real data. The platform says these five carry sector-beating fundamentals at discounted prices. The article says three of the five reported news this week that the quality score has not yet seen, and that a fair value model reading a healthcare company in 2026 is reading a snapshot of a business whose guidance can move 8% in a morning. Transparent investors use both.

The Four That Cleared and Are Not Here

Nine names cleared all three gates. Five are above. The other four are worth naming, because a list that only shows its winners is a marketing document.

Incyte (INCY) produced the single best composite in the entire 1,026-name scan: Company Strength 88.0, the highest Elite rating in the sector, Deep Value at 32.4% below a fair value of $156.68, Bullish outlook, with Financial Health 85/100 and a Moat of 14/15. It is not on the list for one reason: we published the full case for Incyte two weeks ago, on July 23. The data would have put it first. The library already has it.

Globus Medical (GMED) is the only medical device name in the sector that clears all three gates, which given that devices are down 13.6% on the year is itself the story of this sector. Company Strength 68.0, Deep Value at 43.6% below fair value, Growth 14/15. It is absent for the same reason as Incyte: the case was published on July 7.

Healthcare Services Group (HCSG) scored the highest composite of the nine and was excluded on data integrity rather than merit. Its calculated upside of 76.7% sits inside the reliability band, barely, but the model's fair value of $38.97 sits roughly 39% above the highest published analyst target on the street. When a valuation model disagrees with every professional covering the name by that margin, the responsible move is to say so rather than headline it. The underlying business is doing fine: second quarter EPS of $0.32 against a $0.22 consensus, revenue of $470.8 million.

Harmony Biosciences (HRMY) cleared with Company Strength 66.2 and Deep Value at 55.0% below fair value, but its Growth score of 5.0/15 is the weakest reading in the qualifying group by a wide margin. It is a genuine candidate and it stays on the watch list.

One more name deserves a mention despite failing the screen. Boston Scientific (BSX) is the sector's defining wreck of 2026: down roughly 60% from a September 2025 high of $109.50 after two guidance cuts, with 2026 organic growth guidance now at 6.5% to 8% against a prior 10% to 11%, driven by weaker Watchman volumes. It still scores Company Strength 65.2 Strong with a Bullish outlook and adjusted operating margin that actually rose 70 basis points to 28.4% in the second quarter. It failed on one gate only: at $49.30 against a fair value of $52.59, it reads Fair Value, not Undervalued. A stock can fall 60% and still not be cheap. That is the entire argument for measuring instead of eyeballing.

What Could Go Wrong

The strongest case against this entire list is the simplest one, and it deserves to be made properly rather than waved at. Healthcare in 2026 is not cheap by accident. Every name above is trading below the model's fair value because something in its business has deteriorated or is expected to, and a screen that selects for discounts in a sector with genuine structural problems is a screen that selects for falling knives. Devices are the proof: Boston Scientific has cut guidance twice, Zoetis has cut twice, and in both cases the second cut arrived while the stock already looked cheap after the first. There is no rule that says the cutting stops.

The specific version of that risk, name by name. Zoetis has management on record that July showed no stabilization, US companion animal down 11%, and a competitive environment its CEO described as changed in nature rather than degree. Exelixis has a December 3 PDUFA date that is a genuine binary and a revenue guide that just came down. Aurinia is roughly 95% one drug in one indication. Gilead carries the weakest moat score of the five at 9/15, which is the model flagging patent exposure, and has just spent $11.1 billion buying pipeline, which is what companies with patent exposure do. Regeneron is in the middle of a franchise conversion whose economics are not yet proven.

Then the structural caveat this particular edition carries more heavily than most. Company Strength scores in this scan were calculated on August 1. Exelixis reported August 5, Gilead reported this week, Zoetis and Aurinia both reported August 6. Four of the five quality readings are looking at filings one quarter behind the newest disclosure. The valuation and outlook readings are current to August 6, so the discounts are real against current prices, but the quality column will re-run and it may not land in the same place. Zoetis is the obvious candidate to move.

Finally, the honest frame around the sub-sector finding. The observation that biotech has the lowest Bullish rate in the sector while posting the best returns is a real measurement, but it cuts both ways. It may mean the biotech rally is being driven by companies with no fundamentals to score, which is the reading offered above. It may also mean the platform's scoring system is structurally unable to evaluate pre-revenue clinical-stage companies and is therefore blind to exactly where the returns came from. Both are consistent with the data. This publication holds the first view because it does not price hope, but the second is not unreasonable, and anyone who bought XBI in January is up 25% while our screen was calling almost all of it unscoreable.

The Bottom Line

Scan a thousand healthcare companies and the sector stops looking like a sector. Eighty-two percent fail the quality screen outright. Three names in the entire universe rate Elite. The Bullish rate is under 8%. And the sub-sector delivering the year's best returns holds the smallest concentration of names the engine will vouch for, while the one down 13.6% holds nearly four times that share. The 5.5% index return that made healthcare look like a mild laggard was averaging a biotech melt-up against a device collapse, and it described neither.

Nine names clear every gate. Two more were thrown out for printing upside figures the model cannot support, and saying so costs nothing except the appearance of a longer list. Of the nine, one was already published two weeks ago, one a month ago, one disagrees with every analyst covering it, and one has a growth score of five. That leaves five, and even those come with the caveat printed in the callout: four of them filed results in the eight days before this went out, and the quality column has not seen them yet. Zoetis is on this list with a Strong rating and a guidance cut that landed the morning before publication, and both of those facts appear above because both are true.

That is the Wealth Engine Pro approach. Run the full scan rather than the convenient subset, publish the exclusions by name, date the scores so readers know what the model has and has not absorbed, and let the sub-sector arithmetic say something the price chart was hiding. Next Friday the quarterly Strong and Undervalued edition runs its post-Q2 refresh across the whole market, and these five join the public record where the scores will grade what the next round of filings does to them. The sector ETF says healthcare is having a quiet year. The scan says four names in five are already broken and the survivors are not where the returns went.